Table 5.
Immediate risk of precancer and cancer between older and younger group with AGC cytology with and without concurrent squamous cell abnormalities.
| Group | Squamous lesions | Glandular lesions | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age, y | Total | HSIL+, No. (%) | p | SCC, No. (%) | p | AIS+/AEH+, No. (%) | p | AC, No. (%) | p | |
| AGC + Sq | 40-year cutoff | 0.604 | NS | 0.715 | 0.707 | |||||
| ≥40 years | 31/43 | 2 (6.5%) | 0 | 8 (25.8%) | 7 (22.6%) | |||||
| 45-year cutoff | 0.502 | NS | 0.804 | 0.381 | ||||||
| ≥45 years | 26/43 | 2 (7.7%) | 0 | 8 (30.8%) | 7 (26.9%) | |||||
| 50-year cutoff | 0.133 | NS | 0.174 | 0.019 | ||||||
| ≥50 years | 18/43 | 2 (11.1%) | 0 | 7 (38.9%) | 7 (38.9%) | |||||
| 55-year cutoff | 0.490 | NS | 0.277 | 0.046 | ||||||
| ≥55 years | 14/43 | 1 (7.1%) | 0 | 6 (42.9%) | 6 (42.9%) | |||||
| AGC-Alone | 40-year cutoff | 0.890 | 0.630 | 0.145 | 0.002 | |||||
| ≥40 years | 516/726 | 15 (2.9%) | 4 (0.8%) | 69 (13.4%) | 57 (11.1%) | |||||
| 45-year cutoff | 0.825 | 0.885 | 0.000024 | <0.0001 | ||||||
| ≥45 years | 361/726 | 9 (2.5%) | 3 (0.8%) | 63 (17.5%) | 54 (15.0%) | |||||
| 50-year cutoff | 0.957 | 0.553 | 0.00004 | <0.0001 | ||||||
| ≥50 years | 223/726 | 6 (2.7%) | 2 (0.9%) | 44 (19.7%) | 42 (18.8%) | |||||
| 55-year cutoff | 1.000 | 0.539 | 0.000001 | <0.0001 | ||||||
| ≥55 years | 122/726 | 3 (2.5%) | 1 (0.8%) | 31 (25.4%) | 30 (24.6%) | |||||
| AGC | 40-year cutoff | 0.819 | 0.636 | 0.212 | 0.002 | |||||
| ≥40 years | 547/769 | 17 (3.1%) | 4 (0.7%) | 77 (14.1%) | 64 (11.7%) | |||||
| 45-year cutoff | 0.960 | 0.904 | 0.000017 | <0.0001 | ||||||
| ≥45 years | 387/769 | 11 (2.8%) | 3 (0.8%) | 71 (18.3%) | 61 (15.8%) | |||||
| 50-year cutoff | 0.498 | 0.566 | 0.000008 | <0.0001 | ||||||
| ≥50 years | 241/769 | 8 (3.3%) | 2 (0.8%) | 51 (21.2%) | 49 (20.3%) | |||||
| 55-year cutoff | 0.968 | 0.553 | <0.0001 | <0.0001 | ||||||
| ≥55 years | 136/769 | 4 (2.9%) | 1 (0.7%) | 37 (27.2%) | 36 (26.5%) | |||||
AC, adenocarcinoma; AEH, atypical endometrial hyperplasia; AGC, atypical glandular cell; AGC + Sq, atypical glandular cells with concurrent squamous cell abnormalities; AGC-alone, atypical glandular cells without concurrent squamous cell abnormalities; AIS, adenocarcinoma in situ; hrHPV, high risk human papillomavirus; HSIL, high-grade squamous intraepithelial lesion; SCC, squamous cell carcinoma; NS, not significant.